Detection of tau deposition in normal brain aging and neurodegenerative disorders using tau imaging with [C-11]PBB3 and PET

Detection of tau deposition in normal brain aging and neurodegenerative disorders using tau imaging with [C-11]PBB3 and PET - Tau imaging of normal aging and nenrodegeneration with [C-11]PBB3

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014087

Enrollment

Registered

2014-06-01

Start date

2014-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers and patients with neurodegenerative disorders

Interventions

The dosage in the vein of , [C-11]PiB, [F-18]FDG for PET/CT imaging.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Cognitively normal subjects or subjects who have neurodenegerative disorders. The subjects who has intention to participate in this study, and signed informed consent. 2. Male and female subjects of >= 20 years, old. 3. The subject who was judged by clinical investigator by means of physical examination and laboratory tests to be eligible as a participant in this study.

Exclusion criteria

Exclusion criteria: 1.The subject who has dysfunction in the liver / kidney. 2.The subjects having cardiac failure. 3.The subject with a history of a drug or food allergy. 4. Pregnant or woman who has a chance of pregnant. 5.The subject who was judged by the clinical investigator to be inappropriate as a participant in this study.

Design outcomes

Primary

Measure	Time frame
Standardized uptake value ratio (SUVR)	—

Countries

Japan

Contacts

Public ContactKenji Ishii

Tokyo Metropolitan Institute of Gerontology Research Team for Neuroimaging

ishii@pet.tmig.or.jp+81-3-3964-3241

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026